These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24045678)

  • 21. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
    Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
    Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
    Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
    Speroff L; Gass M; Constantine G; Olivier S;
    Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial.
    Simon JA; Gaines T; LaGuardia KD;
    Menopause; 2016 Nov; 23(11):1214-1221. PubMed ID: 27760081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.
    Freeman EW; Guthrie KA; Caan B; Sternfeld B; Cohen LS; Joffe H; Carpenter JS; Anderson GL; Larson JC; Ensrud KE; Reed SD; Newton KM; Sherman S; Sammel MD; LaCroix AZ
    JAMA; 2011 Jan; 305(3):267-74. PubMed ID: 21245182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms.
    Speroff L; Haney AF; Gilbert RD; Ellman H;
    Menopause; 2006; 13(3):442-50. PubMed ID: 16735941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
    Pollack MH; Zaninelli R; Goddard A; McCafferty JP; Bellew KM; Burnham DB; Iyengar MK
    J Clin Psychiatry; 2001 May; 62(5):350-7. PubMed ID: 11411817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Esmirtazapine treatment of postmenopausal vasomotor symptoms: two randomized controlled trials.
    Birkhaeuser M; Bitzer J; Braat S; Ramos Y
    Climacteric; 2019 Jun; 22(3):312-322. PubMed ID: 30712391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
    Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
    Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
    Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
    Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial.
    Caan B; LaCroix AZ; Joffe H; Guthrie KA; Larson JC; Carpenter JS; Cohen LS; Freeman EW; Manson JE; Newton K; Reed S; Rexrode K; Shifren J; Sternfeld B; Ensrud K
    Menopause; 2015 Jun; 22(6):607-15. PubMed ID: 25405571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women.
    Stevens RE; Hanford K; Wason S; Cusack SL; Phelps KV
    Int J Fertil Womens Med; 2000; 45(4):264-72. PubMed ID: 10997482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.
    Golden RN; Nemeroff CB; McSorley P; Pitts CD; Dubé EM
    J Clin Psychiatry; 2002 Jul; 63(7):577-84. PubMed ID: 12143913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.
    Stearns V; Isaacs C; Rowland J; Crawford J; Ellis MJ; Kramer R; Lawrence W; Hanfelt JJ; Hayes DF
    Ann Oncol; 2000 Jan; 11(1):17-22. PubMed ID: 10690382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Another option for menopausal vasomotor symptoms without negative impact on weight and sexual function.
    Bachmann G
    Menopause; 2014 Oct; 21(10):1036-7. PubMed ID: 25072955
    [No Abstract]   [Full Text] [Related]  

  • 37. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
    Archer DF; Dupont CM; Constantine GD; Pickar JH; Olivier S;
    Am J Obstet Gynecol; 2009 Mar; 200(3):238.e1-238.e10. PubMed ID: 19167693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of paroxetine for the treatment of vasomotor symptoms.
    Slaton RM; Champion MN; Palmore KB
    J Pharm Pract; 2015 Jun; 28(3):266-74. PubMed ID: 25107421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.
    Handley AP; Williams M
    J Am Assoc Nurse Pract; 2015 Jan; 27(1):54-61. PubMed ID: 24944075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial.
    LaCroix AZ; Freeman EW; Larson J; Carpenter JS; Joffe H; Reed SD; Newton KM; Seguin RA; Sternfeld B; Cohen L; Ensrud KE
    Maturitas; 2012 Dec; 73(4):361-8. PubMed ID: 23031421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.